SLC5A2 and diabetic neuropathy: In light of this, our study focuses on evaluating the short-term effects of SGLT-2 inhibitor (dapagliflozin or empagliflozin) therapy on diabetic neuropathy-related measures, hydroxyl radical markers, abnormal albuminuria, and RBC parameters in patients with type 2 diabetes mellitus.